| Mr Bereket T Woldemariam, PA-C | |
|
315 W 15th St, Liberal, KS 67901-2455 | |
| (620) 629-6477 | |
| (620) 629-6651 |
| Full Name | Mr Bereket T Woldemariam |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 10 Years |
| Location | 315 W 15th St, Liberal, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578950119 | NPI | - | NPPES |
| 201129150A | Medicaid | KS | |
| 200647940A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 1501810 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carroll Hospital Center | Westminster, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Medicine Associates Pa Pc | 8022914522 | 382 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.
One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.
Information on the gene sequences of H5N1 viruses is important for vaccine development, the preparation of reagents used for diagnostic purposes, and monitoring for drug-resistant strains.
Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.
Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Bereket T Woldemariam, PA-C Po Box 1215, Attn Clinic Billing Office, Liberal, KS 67905-1215 Ph: (620) 629-6638 | Mr Bereket T Woldemariam, PA-C 315 W 15th St, Liberal, KS 67901-2455 Ph: (620) 629-6477 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.
One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.
Information on the gene sequences of H5N1 viruses is important for vaccine development, the preparation of reagents used for diagnostic purposes, and monitoring for drug-resistant strains.
Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.
Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.
› Verified 1 days ago
Unnati Basnyat, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 315 W 15th St, Liberal, KS 67901 Phone: 620-629-6477 Fax: 620-629-6651 | |
Lauren Taylor Boyce, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 315 W 15th St, Liberal, KS 67901 Phone: 620-629-6477 Fax: 620-629-6651 | |
Marlon S Bazan, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 315 W 15th St, Liberal, KS 67901 Phone: 620-629-6477 Fax: 620-629-6651 | |
Elyse Ann Jablonski, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 315 W 15th St, Liberal, KS 67901 Phone: 620-629-6477 Fax: 620-629-6651 | |
Mr. Bishal Bista, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 315 W 15th St, Liberal, KS 67901 Phone: 620-629-6477 Fax: 620-629-6651 | |
Mr. Derick N. Samafuhbi, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 315 W 15th St, Liberal, KS 67901 Phone: 620-629-6477 Fax: 620-629-6651 |